Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol + Ramucirumab in Advanced Gastric/Esophageal Cancer
NCT02970539Phase 1Unknown
- Sponsor
- Athenex
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel + encequidar in gastric cancer (GC), esophageal cancer and gastroesophageal junction adenocarcinoma, sponsored by Athenex. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
paclitaxel + encequidar
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02970539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970539.